Orphan Drugs Market Size & Share to Surpass USD 424.0 billion by 2034, Rising a CAGR 6.9% | Analysis by Transparency Market Research, Inc.
26 sept. 2024 07h14 HE
|
Transparency Market Research
Wilmington, Delaware, United States, Transparency Market Research Inc. -, Sept. 26, 2024 (GLOBE NEWSWIRE) -- The orphan drugs market (희귀의약품 시장) was worth US$ 195.0 billion in 2023. The market is...
Lifecore Biomedical to Participate at Upcoming Industry Conferences and Events
25 sept. 2024 16h05 HE
|
Lifecore Biomedical, Inc.
CHASKA, Minn., Sept. 25, 2024 (GLOBE NEWSWIRE) -- Lifecore Biomedical, Inc. (NASDAQ: LFCR) (“Lifecore”), a fully integrated contract development and manufacturing organization (“CDMO”), today...
PRISM MarketView Features Q&A with Dr. Michael Chancellor: Lipella Pharmaceuticals Advances Innovative Treatments for Hemorrhagic Cystitis During Urology Awareness Month
25 sept. 2024 08h30 HE
|
PRISM MarketView
PRISM MarketView Features Q&A with Dr. Michael Chancellor: Lipella Pharmaceuticals Advances Innovative Treatments for Hemorrhagic Cystitis
Spherix Global Insights Expands into Financial Services, Empowering Asset Managers and Hedge Funds with Critical Pharmaceutical Market Insights
25 sept. 2024 08h16 HE
|
Spherix Global Insights
EXTON, PA, Sept. 25, 2024 (GLOBE NEWSWIRE) -- Spherix Global Insights, a leading independent market intelligence and advisory firm, is expanding its specialized offerings to buy-side financial firms...
Chronic Kidney Disease (CKD) Drugs Market is projected to reach USD 23.8 Billion, garnering a 4.2% CAGR from 2024 to 2034: Transparency Market Research, Inc.
24 sept. 2024 08h32 HE
|
Transparency Market Research
Wilmington, Delaware, United States, Transparency Market Research Inc. -, Sept. 24, 2024 (GLOBE NEWSWIRE) -- The global chronic kidney disease (CKD) drugs market (만성신장질환(CKD) 치료제 시장) was projected...
Lipella Pharmaceuticals Reports Encouraging Early Tolerability Results in Phase 2a Trial of LP-310 for Oral Lichen Planus
24 sept. 2024 08h00 HE
|
Lipella Pharmaceuticals Inc.
Lipella Pharmaceuticals Reports Encouraging Early Tolerability Results in Phase 2a Trial of LP-310 for Oral Lichen Planus
Tea Extract Market is expected to generate a revenue of USD 8.23 Billion by 2031, Globally, at 7.67% CAGR: Verified Market Research®
23 sept. 2024 10h00 HE
|
Verified Market Research
Lewes, Delaware, Sept. 23, 2024 (GLOBE NEWSWIRE) -- The Global Tea Extract Market Size is projected to grow at a CAGR of 7.67% from 2024 to 2031, according to a new report published by Verified...
Labviva Introduces Real Time Inventory Management System for Life Sciences Purchasing
19 sept. 2024 09h00 HE
|
Labviva
Labviva, the leading AI procurement platform for life sciences, today announced the general availability of its automated Inventory Management System.
Lifecore Biomedical Announces High-Speed, Multi-Purpose 5-Head Isolator Filler is GMP-Ready and Operational
19 sept. 2024 07h00 HE
|
Lifecore Biomedical, Inc.
Installation and Qualification Successfully Completed for Closed-System Filler for Pre-Filled Syringes, Vials, and Cartridges Offers State-of-the-Art Speed and Aseptic Isolation Required for...
Io Therapeutics, Inc., presented data from studies of IRX4204, the company’s phase II clinical stage RXR agonist for treatment of normal aging-related neurodegeneration, at the FASEB Science Research Conference on Cellular and Molecular Mechanisms of Brain Aging
18 sept. 2024 11h07 HE
|
Io Therapeutics, Inc.
Io Therapeutics, Inc., presented on IRX4204 for treatment of brain aging, at the FASEB Conference on Cellular and Molecular Mechanisms of Brain Aging